Barclays
ARQT icon

Barclays’s Arcutis Biotherapeutics ARQT Stock Holding History

Barclays’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-111,500
Closed -$1.56M – 5476
2025
Q2 		$1.56M Buy
+111,500
New +$1.56M ﹤0.01% 3037
2024
Q3 		– Sell
-71,700
Closed -$667K – 5282
2024
Q2 		$667K Buy
+71,700
New +$648K ﹤0.01% 2852

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays's ARQT Position: Q1 2026 in Review

Barclays reduced its Arcutis Biotherapeutics (ARQT) stake by 91% in Q1 2026, selling an estimated $7.72M and leaving 28,965 shares worth $682K. The position accounts for ﹤0.01% of the portfolio, ranked #2993.

Barclays first reported a position in ARQT in Q1 2022 and has held it in 17 quarters since. The position peaked at $17.5M in Q4 2022. 269 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Barclays held 28,965 shares of Arcutis Biotherapeutics worth $682K as of Q1 2026.
  • Barclays sold 302,613 Arcutis Biotherapeutics shares in Q1 2026, an estimated $7.72M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2993 holding.
  • Barclays first reported a position in Arcutis Biotherapeutics in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Arcutis Biotherapeutics position peaked at $17.5M in Q4 2022.
  • 269 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.